Author

J. W. Askew

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:differential expression· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

D. Chatterjee· 3 shared D. H. Huisman· 3 shared H. M. Vieira· 3 shared K. W. Fisher· 3 shared R. A. Svoboda· 3 shared R. E. Lewis· 3 shared C. Rao· 2 shared A. S. Ireland· 1 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. Chatterjee

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

KSR1 mediates small-cell lung carcinoma tumor initiation and cisplatin resistance

D. Chatterjee, R. A. Svoboda, D. H. Huisman, B. J. Drapkin, H. M. Vieira, C. Rao, J. W. Askew, K. W. Fisher, R. E. Lewis

This study identifies KSR1 as a critical regulator of SCLC tumor initiation and cisplatin resistance, showing that its disruption enhances cisplatin toxicity and reduces tumor-initiating cells.

bioRxiv · Feb 23, 2024Cancer Biology

SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status

B. Daley, H. M. Vieira, C. Rao, J. M. Hughes, Z. M. Beckley, D. H. Huisman, D. Chatterjee, N. E. Sealover, K. Cox, J. W. Askew, R. A. Svoboda, K. W. Fisher, R. E. Lewis, R. L. Kortum

This study shows that targeting SOS1 or KSR1 enhances MEK inhibitor efficacy and prevents resistance in KRAS-mutated cancers, depending on specific KRAS and co-mutation status.

bioRxiv · Dec 6, 2022Cancer Biology

KSR2 promotes self-renewal and clonogenicity of small-cell lung carcinoma

D. H. Huisman, D. Chatterjee, R. A. Svoboda, H. M. Vieira, A. S. Ireland, S. Skupa, J. W. Askew, D. E. Frodyma, L. Girard, K. W. Fisher, M. Kareta, J. Minna, T. G. Oliver, R. E. Lewis

This study shows KSR2 promotes self-renewal and clonogenicity in ASCL1-subtype SCLC by enhancing ERK signaling and tumor initiating capacity.

bioRxiv · Feb 11, 2022Cancer Biology